Skip to Content
  • Merry Christmas From the FDA

    I see that the FDA is in the holiday spirit – they’ve told Ariad that they can bring Iclusig back to the market in the US, subject to restrictions,… Read More
  • 23 And Me And the FDA

    As everyone will have heard the personal-genomics company 23 and Me was told by the FDA to immediately stop selling their product, a direct-to-consumer DNA sequ… Read More
  • Sarepta’s Approval Woes

    I briefly mentioned Sarepta and etiplirsen, their proposed therapy for Duchenne muscular dystrophy (DMD) in September. In that post, I made reference to the … Read More
  • The Other Shoe Drops at Ariad

    Ever since Iclusig (ponatinib) (note: fixed that name as an update) ran into trouble with blood-cloting side effects, Ariad has had a huge uncertain cloud block… Read More
  • Ariad (And Its Drug) In Trouble

    Ariad’s Inclusig (ponatimib) is in even more trouble than it looked like, and that was already a lot. The company announced earlier this morning that its… Read More
  • Value For the Money

    BioCentury always does a big issue for the fall, entitled “Back to School”. They often use this as a state-of-biopharma platform, going into depth o… Read More
Page 10 of 24« First...89101112...20...Last »